Switching From Wegovy or Zepbound Injections to the Wegovy Pill — What the First Real-World Data Show

Bottom Line

Novo Nordisk reported at the 2026 European Association for the Study of Diabetes meeting that 194 people who switched from weekly injections to the Wegovy pill lost an average of an additional 4.1% of body weight over three months. That is a useful signal that many people do not regain on the pill, but it is a company-presented, early, uncontrolled analysis built on self-reported weights and limited to people who stayed on the pill. It cannot tell us whether switching is as good as staying on injections, which injection people came from, or how many people stopped.

Background

The Wegovy pill, once-daily oral semaglutide 25 mg, was approved by the FDA, as announced by Novo Nordisk on December 22, 2025, and reached U.S. patients in early January 2026 (Novo Nordisk release). Its pivotal trial, OASIS 4, enrolled people who were not on injectables: after 64 weeks they lost 13.6% of body weight versus 2.2% on placebo when everyone assigned to the pill is counted (treatment-policy), and 16.6% among people who stayed on treatment (trial-product estimand) (Pharmacy Times). Neither number says anything about people who start the pill after injections.

That is the group many patients are asking about: people on Wegovy or Zepbound who dislike needles, face travel or storage hassles, or want a simpler maintenance routine and are wondering about the Wegovy pill. We have discussed a different pill for this situation, orforglipron, in our review of maintenance after Wegovy or Zepbound; OCTANE is the first look at the oral semaglutide route.

What OCTANE Found

OCTANE is a retrospective cohort analysis by Novo Nordisk and the Ro telehealth platform, presented as late-breaking abstract LBA 59 on September 30, 2026 (Novo Nordisk release). It has not yet been published as a full peer-reviewed paper (Medical Daily).

• Who: 194 adults who switched from injectable semaglutide or tirzepatide to the pill between January 5 and February 7, 2026, with an average starting weight of 221.6 lb.
• Result: average weight change of 4.1% (about 8.8 lb) at three months, measured from the day of the switch (P<0.001); 40.7% lost at least 5%.
• BMI: the share with a BMI of 30 or higher fell from 87.1% to 65.5%.
• Patient-reported benefit: 4% of those with available data reported at least one improvement, such as better-fitting clothes; the denominator was not given.
• Time between drugs: an average of 36.8 days from the last injectable prescription to starting the pill.

Limitations

• No comparison group. There is no arm of people who stayed on injections, so the study cannot show that switching works as well, better, or worse. Novo’s own release says real-world studies show associations and cannot determine cause.
• Survivors only. Only people who stayed on the pill for three months with no gap longer than 30 days were counted. Anyone who stopped because of side effects, cost or lack of effect is invisible, so the average is likely to be flattering.
• Self-reported weights. Baseline weight (within 30 days) and three-month weight (±15 days) were self-reported, not measured in a clinic.
• Unknown mix of prior drugs, doses and prior loss. Results were not reported separately for people coming from semaglutide versus tirzepatide, no minimum prior injection duration or weight loss was required, and doses and side effects were not reported.
• An unexplained inconsistency. The release lists eligibility as BMI 27 to 29.9, yet the average baseline BMI was 34.5 and 87.1% of participants had a BMI of 30 or higher.
• Industry-affiliated analysis. The study was conducted by Novo Nordisk and Ro, and the only commentary attached to the coverage came from Novo’s chief scientific officer and a co-author; no independent expert was quoted. Novo’s executive also said many people do better on the pill, which this study did not test (Medical Daily).

BeLite Clinical Perspective

Switching can make sense for the right patient, and a pill is a real convenience for people who are stable and want to simplify. But the evidence is not yet strong enough to promise that someone who is doing well on Zepbound or Wegovy injections will do equally well on a pill. The safest way to approach it is as a monitored change, not a swap: a planned transition, a check-in on weight and appetite at four to six weeks, and a clear plan to return to the injection if appetite returns or weight rises. The Foundayo (orforglipron) page describes another oral option; Lilly states it can be taken at any time of day without food or water restrictions (Lilly release), which some patients find easier.

Anyone considering stopping an injection for any reason should read what we know about the risks and rebound after stopping first. A switch is not the same as stopping, but the stakes are similar if the new treatment doesn’t hold the weight.

Whichever form you take, protect your muscle and your results with enough protein and strength training. See our eating guide for patients on Zepbound and Wegovy and how much muscle you lose on GLP-1 medications.

FAQs

Q: Can I switch from Zepbound or Wegovy injections to the Wegovy pill?

A: Many people ask, and some physicians do it, but there is no randomized trial showing the pill holds weight as well as the injection after a switch. The decision should be made with your prescriber, with monitoring afterward.

Q: Will I keep losing weight on the pill?

A: In OCTANE, people who stayed on the pill for three months lost an additional 4.1% on average. That excludes people who stopped, and the weights were self-reported, so your result could be different.

Q: Is the pill as strong as the injection?

A: Not established. The pill’s own trial (OASIS 4) showed 13.6% weight loss at 64 weeks when everyone assigned to the pill is counted, and 16.6% in people who stayed on treatment. Those are different populations from OCTANE, and no trial here compares the pill with injections.

Q: Why does it matter that OCTANE was presented by Novo Nordisk?

A: A company has an interest in showing its product in a good light, and the analysis was a retrospective look at a favorable subset of patients. That doesn’t make the data wrong, but it means the results need independent confirmation.

Q: What if I’m doing well on the injection?

A: Then there is no medical reason to change. A switch is about preference, convenience or cost, and it should be weighed against the lack of evidence that the pill keeps weight off equally well.

References

1. Novo Nordisk. People switching from weight-loss injections to Novo’s Wegovy pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026. September 30, 2026.
2. Medical Daily. Wegovy pill switching: OCTANE results at EASD 2026.
3. Patient Care Online. Switch to oral semaglutide linked to 4.1% weight loss at 3 months in new study. October 5, 2026.
4. Novo Nordisk. FDA approves the Wegovy pill. December 22, 2025.
5. Pharmacy Times. FDA approves first oral GLP-1 for weight management. December 23, 2025.
6. Eli Lilly. Foundayo (orforglipron) release, June 7, 2026.
7. BeLite Medical Center. Orforglipron for maintenance after Wegovy or Zepbound.
8. BeLite Medical Center. What happens after stopping Wegovy or Zepbound.